Rankings / Metabolic Health

Maridebart cafraglutide (MariTide)

Metabolic Health · GLP-1 agonist + GIP antagonist

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

glp-1gippeptideinvestigational
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Maridebart cafraglutide (MariTide) as B (6.8/10) based on strong phase 2 evidence, high benefit magnitude, and a med-risk safety profile.

Amgen.

Studied, labeled, or reported-use context: 140-420 mg SC every 4-8 weeks; titration schedules vary — Investigational; not individualized guidance.

What the evidence says

Amgen. Phase 2 (Jastreboff NEJM 2025, n=592, NCT05669599): obesity cohort -12.3% to -16.2% body weight at 52 weeks vs -2.5% placebo; T2D cohort -8.4% to -12.3% with HbA1c -1.2 to -1.6 percentage points. Once-monthly dosing is the differentiator vs weekly GLP-1s. Counterintuitive that BOTH GIP agonism (tirzepatide) AND antagonism (MariTide) produce additive weight loss with GLP-1 — pharmacology not fully resolved.

Mechanism

Long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism (the inverse of tirzepatide's GIP agonism); enables once-monthly dosing

Studied, labeled, or reported dose & route

140-420 mg SC every 4-8 weeks; titration schedules vary

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Maridebart cafraglutide (MariTide)'s effects?
Read Off Label rates the evidence for Maridebart cafraglutide (MariTide) as Strong Phase 2 and the benefit magnitude as high, producing an overall grade of B (6.8/10). Amgen.
What safety findings are reported for Maridebart cafraglutide (MariTide)?
Maridebart cafraglutide (MariTide) has a med risk profile in the database. Med (GI events common but mitigated by dose escalation) Legal status: Investigational (Phase 3).
What doses or routes are reported for Maridebart cafraglutide (MariTide)?
140-420 mg SC every 4-8 weeks; titration schedules vary This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Maridebart cafraglutide (MariTide) work?
Long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism (the inverse of tirzepatide's GIP agonism); enables once-monthly dosing

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.